These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38494113)

  • 1. Advancing assessment of asthma control with a composite tool: The Asthma Impairment and Risk Questionnaire.
    Chipps BE; Zeiger RS; Beuther DA; Wise RA; McCann W; Reibman J; George M; Gilbert I; Eudicone JM; Coyne KS; Harding G; Murphy KR
    Ann Allergy Asthma Immunol; 2024 Jul; 133(1):49-56. PubMed ID: 38494113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Clinical Characteristics and Biomarkers on Asthma Impairment and Risk Questionnaire Exacerbation Prediction Ability.
    Murphy KR; Beuther DA; Chipps BE; Wise RA; McCann WA; Reibman J; George M; Gilbert I; Eudicone JM; Gandhi HN; Ross M; Coyne KS; Zeiger RS
    J Allergy Clin Immunol Pract; 2024 Aug; 12(8):2092-2101.e4. PubMed ID: 38705273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of the Asthma Impairment and Risk Questionnaire (AIRQ): A Composite Control Measure.
    Murphy KR; Chipps B; Beuther DA; Wise RA; McCann W; Gilbert I; Eudicone JM; Gandhi HN; Harding G; Coyne KS; Zeiger RS;
    J Allergy Clin Immunol Pract; 2020; 8(7):2263-2274.e5. PubMed ID: 32387166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating construct validity of the Asthma Impairment and Risk Questionnaire using a 3-month exacerbation recall.
    Chipps BE; Murphy KR; Wise RA; McCann WA; Beuther DA; Reibman J; George M; Gilbert I; Eudicone JM; Gandhi HN; Harding G; Ross M; Zeiger RS
    Ann Allergy Asthma Immunol; 2022 May; 128(5):544-552.e3. PubMed ID: 35123077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Asthma Impairment and Risk Questionnaire (AIRQ) Control Level Predicts Future Risk of Asthma Exacerbations.
    Beuther DA; Murphy KR; Zeiger RS; Wise RA; McCann W; Reibman J; George M; Gilbert I; Eudicone JM; Gandhi HN; Ross M; Coyne KS; Chipps B
    J Allergy Clin Immunol Pract; 2022 Dec; 10(12):3204-3212.e2. PubMed ID: 35998877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing meaningful change in the Asthma Impairment and Risk Questionnaire.
    McCann W; Murphy KR; Zeiger RS; Beuther DA; Wise RA; Reibman J; George M; Gilbert I; Eudicone JM; Gandhi HN; Cutts K; Coyne KS; Chipps B
    Ann Allergy Asthma Immunol; 2024 Aug; 133(2):152-158. PubMed ID: 38369256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Asthma Impairment and Risk Questionnaire enhances the assessment of asthma control.
    Chipps B; Zeiger RS; Beuther DA; Reibman J; Wise RA; McCann W; Gilbert I; Eudicone JM; Gandhi HN; Harding G; Cutts K; George M; Murphy KR
    Ann Allergy Asthma Immunol; 2023 Oct; 131(4):436-443.e1. PubMed ID: 37105501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Asthma Control Test (ACT) as an alternative tool to Global Initiative for Asthma (GINA) guideline criteria for assessing asthma control in Vietnamese outpatients.
    Nguyen VN; Chavannes N; Le LT; Price D
    Prim Care Respir J; 2012 Mar; 21(1):85-9. PubMed ID: 22027946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Asthma control assessment in a pediatric population: comparison between GINA/NAEPP guidelines, Childhood Asthma Control Test (C-ACT), and physician's rating.
    Deschildre A; Pin I; El Abd K; Belmin-Larrar S; El Mourad S; Thumerelle C; Le Roux P; Langlois C; de Blic J
    Allergy; 2014 Jun; 69(6):784-90. PubMed ID: 24725204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of the German version of the Asthma Impairment and Risk Questionnaire (AIRQ).
    Kanniess F; Defosse K; Lommatzsch M; Schultz T; Timmermann H; Schmidt O; Heindl S; Baumann HJ; Buhl R; Taube C; Höing F; Korn S
    Pneumologie; 2024 Nov; 78(11):912-921. PubMed ID: 38991526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Asthma Control Test (ACT) as a predictor of GINA guideline-defined asthma control: analysis of a multinational cross-sectional survey.
    Thomas M; Kay S; Pike J; Williams A; Rosenzweig JR; Hillyer EV; Price D
    Prim Care Respir J; 2009 Mar; 18(1):41-9. PubMed ID: 19240948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determining the Best Tool Comparable with Global Initiative for Asthma Criteria for Assessing Pediatric Asthma Control.
    Akan A; Dibek Mısırlıoğlu E; Civelek E; Kocabaş CN
    Pediatr Allergy Immunol Pulmonol; 2021 Sep; 34(3):89-96. PubMed ID: 34432544
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparing Asthma Control Test with Global Initiative for Asthma Defined Control in Nigerian Adult Asthmatics: A Prospective Cross-sectional study.
    Awopeju OF; Salami OT; Oni OM; Adetiloye A; Kolawole T; Oyewo A; Erhabor GE
    West Afr J Med; 2019; 36(1):29-42. PubMed ID: 30924114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship Between Asthma Control as Measured by the Asthma Impairment and Risk Questionnaire (AIRQ) and Patient Perception of Disease Status, Health-Related Quality of Life, and Treatment Adherence.
    Reibman J; Chipps BE; Zeiger RS; Beuther DA; Wise RA; McCann W; Gilbert I; Eudicone JM; Gandhi HN; Harding G; Cutts K; Coyne KS; Murphy KR; George M
    J Asthma Allergy; 2023; 16():59-72. PubMed ID: 36636702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and validation of a novel risk score for asthma exacerbations: The risk score for exacerbations.
    Bateman ED; Buhl R; O'Byrne PM; Humbert M; Reddel HK; Sears MR; Jenkins C; Harrison TW; Quirce S; Peterson S; Eriksson G
    J Allergy Clin Immunol; 2015 Jun; 135(6):1457-64.e4. PubMed ID: 25258144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of short-acting bronchodilators and cost burden of asthma across Global Initiative for Asthma-based severity levels: Insights from a large US commercial and managed Medicaid population.
    Pollack M; Gandhi H; Tkacz J; Lanz M; Lugogo N; Gilbert I
    J Manag Care Spec Pharm; 2022 Aug; 28(8):881-891. PubMed ID: 35708342
    [No Abstract]   [Full Text] [Related]  

  • 17. Prospective evaluation of current asthma control using ACQ and ACT compared with GINA criteria.
    Korn S; Both J; Jung M; Hübner M; Taube C; Buhl R
    Ann Allergy Asthma Immunol; 2011 Dec; 107(6):474-9. PubMed ID: 22123375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive Properties of the Asthma Control Test and Its Component Questions for Severe Asthma Exacerbations.
    Cajigal S; Wells KE; Peterson EL; Ahmedani BK; Yang JJ; Kumar R; Burchard EG; Williams LK
    J Allergy Clin Immunol Pract; 2017; 5(1):121-127.e2. PubMed ID: 27544712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing Global Initiative for Asthma (GINA) criteria with the Childhood Asthma Control Test (C-ACT) and Asthma Control Test (ACT).
    Koolen BB; Pijnenburg MW; Brackel HJ; Landstra AM; van den Berg NJ; Merkus PJ; Hop WC; Vaessen-Verberne AA
    Eur Respir J; 2011 Sep; 38(3):561-6. PubMed ID: 21406508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accuracy of childhood asthma control test among Thai childhood asthma patients.
    Sommanus S; Direkwattanachai C; Lawpoolsri S; Sitcharungsi R
    Asian Pac J Allergy Immunol; 2018 Sep; 36(3):152-158. PubMed ID: 29223149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.